Psyence Appoints Intellectual Property Expert To Its Board Of Directors
Psyence is pleased to announce the appointment of Christopher Bull to the board of directors of the Company effective immediately.
Psyence Group Announces Closing Of Previously Announced Financing
Psyence announces that it has issued 7,775,964 common shares at a price of CAD$0.12 per common share and 3,887,982 warrants for aggregate proceeds of CAD$ 933,116 to Cantheon Capital LLC.
Psyence Group Announces Closing Of Fourth Round Tranche Of Private Placement And Conversion Of Convertible Debt Note
Psyence is pleased to announce that it has issued 9,043,038 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$1,085,164. This brings the total amount the Company has raised pursuant to the previously announced private placement to CAD $3.04 million ("Aggregate Proceeds").
Psyence Group Announces Cantheon Capital Private Placement
Psyence is pleased to announce that it has entered into a brokered subscription agreement with Cantheon Capital, LLC (“Cantheon”). Cantheon, a fund focussed on listed biotech stocks with near term catalysts,
Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia
Psyence Australia Pty Ltd, has partnered with iNGENū Pty Ltd (iNGENū) to conduct Psyence’s previously announced clinical trial in palliative care. iNGENū is an Australian based, globally focused Contract Research Organization (CRO) with extensive experience working in the psychedelic pharmaceutical drug development and clinical research industry.
Psyence and Eden Labs Announce Extraction and Product Development Collaboration
Psyence is pleased to announce that it has entered into a partnership with Eden Labs LLC, (“Eden Labs”) a product development and extraction technology company that has developed intellectual property and methodologies around the extraction of psilocybin-yielding mushrooms.
Psyence Group Completes Export Of Pharma Grade Psilocybin Extract To UK
Psyence announce that it has exported purified pharmaceutical grade psilocybin mushroom extract to its Contract Development & Manufacturing Organisation (“CDMO”) partner in the United Kingdom.
Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp
Psyence & Newcourt have entered into a definitive business combination agreement (the “Business Combination Agreement”) on January 9, 2023 with Psyence Biomed Corp (“Psyence Biomed”), a wholly owned subsidiary of Psyence, to create a public company (the “Combined Company”) leveraging natural psilocybin in the treatment of palliative care (the “Business Combination”). Psyence Biomed is Psyence’s clinical trial division.
Psyence Signs Letter of Intent with Australian CRO iNGENū
Psyence announce it has signed a Letter of Intent (LOI) with Contract Research Organisation (CRO) iNGENū to execute Psyence’s strategy of clinical development in palliative care. iNGENū is an Australian full-service CRO specialising in clinical trials for psychoactive pharmaceuticals.
Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care
The agreement expands on an existing partnership and grants Psyence the right to commercialize Filament’s natural psilocybin drug candidate PEX010 25mg within palliative care